The medtech industry saw its largest fall in several months last week, but it has rebounded slightly after a couple of bad weeks. A strong start to 2021 hit a skid at the end of February and carried over into March, with MassDevice‘s MedTech 100 index hitting its lowest point on March 8 (102.16). It had […]
Takeda Pharmaceuticals
Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M
Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million. Osaka, Japan-based Takeda exercised its option to acquire Maverick and obtain its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages. Get the full story at our sister site, Drug […]
Evox Therapeutics completes $95.4M Series C
Evox Therapeutics announced today that it raised $95.4 million (£69.2 million) in a Series C financing round. Oxford, England-based Evox’s financing was significantly oversubscribed with high demand from both existing and new investors, according to a news release. Get the full story at our sister site, Drug Delivery Business News.
Corza Medical set to take on ‘almost monopolistic’ surgical giants
Corza Medical, a new venture forged by the financial firepower of private equity giant GTCR, is looking to become a surgical tool supplier that its executive chairman Greg Lucier says can compete with “almost monopolistic” leaders in the space. To mount the challenge, Corza acquired Surgical Specialties Corp., a supplier of surgical sutures and ophthalmic […]
European Commission scrutinizes J&J TachoSil buy
The European Commission said Wednesday that it has opened an in-depth investigation of the proposed $400 million acquisition of Takeda Pharmaceutical’s (TSE:4502;NYSE:TAK) TachoSil surgical sealant patch by Johnson & Johnson (NYSE:JNJ). The commission said it is concerned that the acquisition by J&J’s Ethicon unit may reduce competition and innovation for the supply of dual haemostatic patches, used […]
J&J’s Ethicon buys Takeda’s TachoSil fibrin patch for $400m
Takeda Pharmaceutical (TSE:4502;NYSE:TAK) said yesterday that it’s dealing its TachSil fibrin patch to Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon for $400 million in cash. The Japanese company, which is still digesting last year’s $62 billion acquisition of Shire, said it also agreed to sell its Xiidra lifitegrast ophthalmic solution to Novartis (NYSE:NVS) for $3.4 billion, […]
Takeda reaches $62B deal to buy Shire
After a series of offers, Takeda (TYO:4502) said today that it reached an agreement with Shire (NSDQ:SHPG) to acquire the U.S.-based company in a deal valued at $62 billion. The merger was approved by both companies’ boards of directors, according to Takeda, and is slated to close in the first half of 2019. Takeda investors are wary of the enormous […]
Shire accepts $64B takeover bid from Takeda
Shire (NSDQ:SHPG) said late yesterday it agreed to Takeda Pharmaceutical‘s (TYO:4502) reworked acquisition bid, now worth approximately $64.2 billion (GBP £46 billion). The takeover offer will now go to Shire’s shareholders for approval, having received backing from Dublin, Ireland-based Shire’s board of directors, according to a press release. Read the whole story on our sister site, […]
Report: Takeda raises $60B offer for Shire, nears prelim acquisition agreement
Takeda Pharmaceutical (TYO:4502) has sweetened its approximately $60 billion bid for Shire (NSDQ:SHPG) and is approaching a preliminary agreement for acquisition, according to a new report from Bloomberg. The deal could come to a head as early as today, according to the report, as both companies have been working on a tentative agreement and price for the […]
Allergan, Takeda spar for Shire
Allergan (NYSE: AGN) today confirmed that it’s in the running to acquire Shire (NSDQ:SHPGY), which rejected a $63 billion offer from Takeda Pharmaceutical (TYO:4502). Dublin-based Allergan, which is in the process of slashing 1,400 jobs from its payroll and exploring “strategic actions,” said there’s no guarantee it will make an offer for Shire. Get the full story at our sister […]
Fine-tuning formulation with Fluid Imaging Technologies’ FlowCam
After seven people died in 2013 from serious allergic reactions to Omontys, an injectable anemia drug marketed by Takeda Pharmaceutical (TYO:4502) and Affymax, the companies recalled the product and regulators launched an investigation to find out the cause of such an unexpected rate of anaphylaxis. Omontys was made and cleared in a single-use vial and a multi-use […]
